Research Analysts Offer Predictions for CAPR Q2 Earnings

Capricor Therapeutics Inc (NASDAQ:CAPR) – Equities research analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for Capricor Therapeutics in a research report issued to clients and investors on Thursday, March 20th. HC Wainwright analyst J. Pantginis expects that the biotechnology company will post earnings of ($0.36) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $77.00 price target on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The company had revenue of $11.13 million during the quarter, compared to the consensus estimate of $9.87 million.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $30.00 price objective on shares of Capricor Therapeutics in a research report on Thursday. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat.com, Capricor Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock opened at $14.36 on Friday. The company has a market cap of $652.95 million, a price-to-earnings ratio of -13.55 and a beta of 4.10. Capricor Therapeutics has a one year low of $3.52 and a one year high of $23.40. The firm has a 50-day moving average of $14.06 and a 200-day moving average of $14.50.

Institutional Trading of Capricor Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CAPR. Summit Investment Advisors Inc. boosted its position in Capricor Therapeutics by 54.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 1,345 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Capricor Therapeutics by 172.8% in the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after buying an additional 2,947 shares in the last quarter. Virtus ETF Advisers LLC purchased a new stake in shares of Capricor Therapeutics in the fourth quarter worth $68,000. AlphaQuest LLC bought a new stake in shares of Capricor Therapeutics during the 4th quarter valued at about $78,000. Finally, New York State Common Retirement Fund lifted its holdings in shares of Capricor Therapeutics by 625.0% in the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 5,000 shares during the last quarter. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.